CEO Dr Mark Eccleston has recorded a podcast with Biotech Builders’ Katy Barber. In this episode, Mark speaks about his extensive background and his journey to becoming a CEO. Listen to the podcast here: #DrugDevelopment #LifeSciences #BiotechBuilders

ValiRx went through a successful Structural Reorganisation in 2025 - hear from Mark Eccleston, CEO, as he discusses some of the key benefits. Check out the full video and join in with the conversation at: #val

ValiRx CEO Dr Mark Eccleston is attending and speaking at the CatSci Innovations in Peptide Science 2025 event at Nottingham’s Biocity. If you are at the event today and would like to connect with Mark, please get in touch: #Networking #CancerResearch

Just one day to go until ValiRx CEO, Dr Mark Eccleston, speaks at the CatSci Innovations in Peptide Science 2025 event. If you’re attending and want to connect with Mark to discuss our services and expertise, please get in touch: #Event #CancerResearch

ValiRx CEO, Dr Mark Eccleston will be attending and speaking at the CatSci Innovations in Peptide Science 2025 event and will be speaking about CLX001 – A nanoparticle oncolytic peptide formulation for next-generation cancer therapy at 2pm on Tuesday 1 July. #Event #Networking

Agreement struck with Ambrose Healthcare to license VAL401. We are pleased to announce that Ambrose Healthcare, has opted to license VAL401 to support the treatment of rare and difficult-to-treat pancreatic cancer. Find out more: . #CancerResearch #PDCs

Thank you to everyone who connected with ValiRx CEO, Dr Mark Eccleston at the BIO International Convention last week. If you'd like to learn more about our services and expertise, get in touch: . #BIO2025 #Event #Networking #Assays #AssayDevelopment

Did you miss Dr Mark Eccleston's webinar last week? . Mark presented ValiRx's 2024 results to existing and prospective investors on our website. Catch up on the webinar here: #Assays #AssayDevelopment #CompanyUpdate #CompanyResults

The BIO International Convention begins today, held at the Boston Convention & Exhibition Center. ValiRx CEO Dr Mark Eccleston will be in attendance. To connect with Mark during the convention this week, click here: @IAmBiotech. #BIO2025 #Event

At Inaphaea, we offer cells for purchase and testing services across our biobank of 478 Patient Derived Cell Models, representing 66 cancer indications, including 31 prostate cancer PDCs with RNS-seq data. View more on our website: #MensHealthWeek #PDCs

ValiRx CEO Dr Mark Eccleston is attending the life sciences flagship partnering event next week: The BIO International Convention. If you’d like to book a meeting with Mark, please do so via BIO’s official partnering platform: @IAmBiotech. #BIO2025

ValiRx Investor Webinar - hear from the team this Thursday June 12, at 10am BST. Follow the link below to sign up and submit your questions in advance:. #val #ValiRx #BioTech #ImmunoOncology #TranslationalResearch #BusinessModels #LifeSciences #Innovation

We are pleased to announce that our subsidiary, Cytolytix Ltd and Omios Biologics, a California-based corporation, have entered into an Evaluation and Material Transfer agreement. Find out more about the agreement here: #CancerResearch #AssayDevelopment

ValiRx's Mark Eccleston shares how an unconventional operating model, focused evaluation program & a scalable SPV strategy are shaping the company’s next phase. He also discusses major opportunities in immuno-oncology and the tCRO model. Watch here: #val

ValiRx CEO, Dr Mark Eccleston is attending the 2025 @ASCO Annual Meeting, later this week. Mark will be available to speak to fellow delegates about our drug pipeline and development services. To book a meeting with Mark, get in touch: . #ASCO2025

Mark Eccleston, CEO, discusses Pro-Senescence cancer therapeutics. He explores the science behind the approach, as well as partnerships, funding, and repurposing existing drugs via evaluation agreements. Watch below!. #CancerResearch #DrugDiscovery #val

We recently released an RNS on the Termination of Letter of Intent with TheoremRx. Hear from CEO, Dr Mark Eccleston, as he discusses why we chose this course, and what comes next at ValiRx. Please feel free to submit your questions via our website. #val

ValiRx CEO Mark Eccleston and Director of Research Michelle Barnard are attending the 4th Ace Drug Discovery Summit in London next week. Be sure to catch Mark’s talk on 2 April at 4pm. #4thADDSLondon #DrugDiscovery #CancerResearch #ScientificResearch #Event #Networking

ValiRx CEO Dr Mark Eccleston featured in The Inspirational Leaders magazine. Mark's commitment to accelerating early-stage drug development is a testament to the leadership needed to bring drug candidates to the clinic. @inspiratio29631. Read more:

We've just posted the following update on our investor hub: ValiRx CEO features in the Inspirational Leaders Magazine. Check out the update and join in the conversation at: #AssayDevelopment #BioTech #DrugDiscovery #CancerResearch #ScientificResearch